ATNM:NYE-Actinium Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 10.40

Change

+0.05 (+0.48)%

Market Cap

USD 0.14B

Volume

0.34M

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or adoptive cell therapies. Its lead product candidate is Iomab-B, which is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. The company is also developing Actimab-A, its lead alpha-particle drug candidate that is in a Phase II trial for patients newly diagnosed with AML age 60 and over; and Actimab-M, a drug candidate, for the treatment of patients with penta refractory multiple myeloma in a Phase 1 clinical trial. Its Antibody Warhead Enabling technology platform is currently being utilized in a research collaboration with Astellas Pharma, Inc. The company was founded in 2000 and is based in New York, New York.

Company Website : http://www.actiniumpharma.com

Address : 275 Madison Avenue, New York, NY, United States, 10016

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.18

52 Week High : 19.47

Short Ratio : 1.71

52 Week Low : 4.71

Shorted Shares : 666,252

200 Day Moving Average : 10.66

Shorted Shares Previous Month : 536,834

50 Day Moving Average : 11.18

Shares Held By Insiders : 15.46%

Short Percentage : 5.00%

Shares Held by Institutions : 22.22%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-12-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

-0.93 (-1.36%)

 USD156.25B 27.68 2.61
BHVN Biohaven Pharmaceutical Holdin..

-1.00 (-1.14%)

 USD5.28B N/A N/A
ADCT ADC Therapeutics SA

-2.36 (-6.22%)

 USD2.91B -99,999.99 N/A
ZYME Zymeworks Inc

-0.38 (-0.69%)

 USD2.51B 300.20 N/A
MYOV Myovant Sciences Ltd

+0.93 (+3.96%)

 USD2.13B N/A N/A
RCUS Arcus Biosciences, Inc

+0.85 (+3.13%)

 USD1.76B N/A N/A
CVM CEL-SCI Corporation

-0.45 (-3.64%)

 USD0.48B N/A N/A
PFNX Pfenex Inc

N/A

 USD0.44B 268.67 63.90
RFL Rafael Holdings, Inc

+1.19 (+5.63%)

 USD0.33B N/A N/A
IBIO iBio, Inc

-0.07 (-4.40%)

 USD0.29B N/A N/A

ETFs Containing ATNM

Symbol Name Weight Mer Price(Change) Market Cap
RJZ ELEMENTS Linked to the Ro.. 0.00 % 0.75 %

N/A

 USD4.19M

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 59.02% 73% C 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 59.02% 73% C 94% A
Trailing 12 Months  
Capital Gain 42.08% 63% D 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.08% 63% D 90% A-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 10.90% N/A N/A 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.90% N/A N/A 76% C
Risk Return Profile  
Volatility (Standard Deviation) 29.35% N/A N/A 22% F
Risk Adjusted Return 37.15% N/A N/A 53% F
Market Capitalization 0.14B 53% F 25% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.35 54% F 26% F
Price / Cash Flow Ratio -6.55 37% F 91% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -73.83% 52% F 5% F
Return on Invested Capital -292.59% 17% F 0% N/A
Return on Assets -38.51% 48% F 1% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.71 77% C+ 56% F
Short Percent 4.91% 56% F 47% F
Beta 1.18 70% C- 41% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.